


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>4</sup> : A61K 31/12, 31/22, 31/016 A61K 31/41, 31/19, 31/23	A2	(11) International Publication Number: WO 90/00049 (43) International Publication Date: 11 January 1990 (11.01.90)
(21) International Application Number: PCT/US89/02762		(74) Agent: HALLUIN, Albert, P.; Cetus Corporation, 1400 Fifty-Third Street, Emeryville, CA 94608 (US).
(22) International Filing Date: 23 June 1989 (23.06.89)		
(30) Priority data: 212,957 29 June 1988 (29.06.88) US 324,360 15 March 1989 (15.03.89) US		(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent).
(71) Applicant: CETUS CORPORATION [US/US]; 1400 Fifty-Third Street, Emeryville, CA 94608 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>
(72) Inventors: NITECKI, Danute, E. ; 2296 Virginia Street, Berkeley, CA 94709 (US). MORELAND, Margaret ; ALDWIN, Lois ; 179 Lakeshore Drive, San Mateo, CA 94402 (US). LEVENSON, Corey, H. ; 311 Mandalay Road, Oakland, CA 94618 (US). BRAUDE, Irwin ; 348 Barrett Circle, Danville, CA 94526 (US). MARK, David, F. ; 217 Stanbridge Court, Danville, CA 94526 (US).		

## (54) Title: IMMUNOSUPPRESSIVE ANALOGUES AND DERIVATIVES OF SUCCINYLACETONE



## (57) Abstract

Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consist of succinylacetyl-proline-PEG, succinylacetyl-NH-PEG, or compounds that have formula (I), wherein n = 1-6; R = CH<sub>3</sub>, CF<sub>3</sub>, -CO<sub>2</sub>R<sup>IV</sup>, (a), or (b); R'<sup>I</sup>, R<sup>II</sup> = H, F, CH<sub>3</sub>, or (c); R<sup>III</sup> = H, -CO<sub>2</sub>R<sup>IV</sup>, (d), (e), or tetrazolyl; R<sup>IV</sup> = H, or alkyl; and that have immunosuppressive activity both *in vivo* and *in vitro* based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.

BEST AVAILABLE COPY

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	FI Finland	ML Maldives
AU Australia	FR France	MR Mauritania
BB Barbados	GA Gabon	MW Malawi
BE Belgium	GB United Kingdom	NL Netherlands
BF Burkina Faso	HU Hungary	NO Norway
BG Bulgaria	IT Italy	RO Romania
BJ Benin	JP Japan	SD Sudan
BR Brazil	KP Democratic People's Republic of Korea	SE Sweden
CF Central African Republic	KR Republic of Korea	SN Senegal
CG Congo	LI Liechtenstein	SU Soviet Union
CH Switzerland	LK Sri Lanka	TD Chad
CM Cameroon	LU Luxembourg	TG Togo
DE Germany, Federal Republic of	MC Monaco	US United States of America
DK Denmark	MG Madagascar	
ES Spain		

5

## IMMUNOSUPPRESSIVE ANALOGUES AND DERIVATIVES OF SUCCINYLACETONE

### Technical Field of the Invention

This invention is in the area of immunology, and specifically relates to immunopharmacology as applied to the development of immunosuppressive drugs that 10 are useful in treating a wide variety of diseases arising from a dysfunctional hyperactive immune system. Compositions and methods of using the same that are particularly useful in treating autoimmune diseases are shown.

### Background of the Invention

There is a continuous search for therapeutics that have immunosuppressive 15 activity, and therefore facilitate organ tissue transplants, as well as being beneficially applied to the treatment of various autoimmune diseases. The basis of organ tissue rejection is known and resides in the histocompatibility two locus (H-2) in the mouse, and the human leucocyte antigen (HLA) complex in the human. Klein, J., et al. Ann. Rev. Immunol. 1:119 (1983). Both systems code for cell surface molecules that are 20 recognized as foreign in a recipient host. Only in those instances where the donor and recipient are genetically identical, that is when the donor and recipient are identical twins, is there little or no chance of rejection of the transplanted organ. However, since the donor and recipient are rarely genetically identical, some degree of histocompatibility antigenic mismatch is present, and hence the application of 25 immunosuppressive drugs is required. This is true, even where donors and recipients are HLA matched, that is, matched with the antigens of the major histocompatibility complex loci, since rejection of the transplant can still arise as a result of mismatching of minor genetic loci that are also involved in rejection.

Immunosuppressive drugs are also widely used in the area of graft versus host 30 rejection, particularly bone marrow transplants. The graft from a donor contains a significant number of immunocompetent lymphoid cells that can mount an effective destructive reaction against host cells. Bone marrow transplants are often employed to treat various malignant diseases, including leukemia. Generally this involves 35 immunologically crippling the leukemic patient, and then transplanting bone marrow from a donor. Unless the lymphoid cells in the donor marrow are suppressed they can

react against recipient tissue antigens, often with dire consequences.

A variety of drugs, and antisera to lymphoid cells are used as immunosuppressives. Particularly useful drugs are corticosteroids, o thiopurine, and cyclosporin. In addition, various monoclonal antibodies, alone or when coupled to a 5 cytotoxic agent are available for ridding the donor marrow of lymphoid cells. P. S. Russell et al., Annual Review Medicine 35:63 (1984). In addition, U.S. Patent 4,670,467 claims succinylacetone (SA, 4, 6-dioxoheptanoic acid) as an immunosuppressive medicament. Succinylacetone is a seven carbon organic ketoacid.

In addition to being used in the area of organ tissue transplantation, and graft 10 versus host disease, immunosuppressive drugs are widely sought after to treat autoimmune diseases. Autoimmunity can generally be defined (Smith, H. and Steinberg, A. Autoimmunity - A Perspective Ann. Rev. Immunol. 1:175 (1983)) as the generation of an immune response against a person's own self components. Autoimmune diseases generally develop spontaneously in humans. Both a person's 15 genetic predisposition, as well as environmental factors may play a role. Those agents which are thought to initiate autoimmunity are poorly defined. However, autoimmunity can be induced in experimental animals by suitable immunization procedures with known antigens. Classical examples of experimentally induced autoimmune diseases in animals are experimental or allergic encephalomyelitis, and 20 adjuvant induced arthritis. The former is induced by immunization with a myelin basic protein, and induces an autoimmune disease having neurological symptoms involving partial or complete paralysis of the hind legs of animals. The latter entails use of any microbacterium for induction of arthritis in rats. Examples of autoimmune diseases in humans include various forms of diabetes systemic lupus erythematosus, myasthenia 25 gravis, chronic thyroiditis, hemolytic anemia, and multiple sclerosis. Additionally, rheumatoid arthritis is often considered an autoimmune disease.

Many autoimmune diseases are thought to occur by different immune mechanisms. This includes a cytotoxic mechanism whereby antibody reacts with antigen, and the resulting complex becomes membrane associated. Often this initiates 30 complement mediated lysis of the involved cells. A second mechanism involves the interaction of lymphoid cells, rather than antibodies and complement, with antigen. Often this results in an inflammatory response, such as that seen in rheumatoid

arthritis.

Immunosuppressive drugs are used to treat autoimmune diseases, much as they are used to treat organ tissue transplants and graft versus host disease. In the clinical arena, cyclosporin A has been shown to be effective in treating various experimentally induced autoimmune diseases. Shevach, E. *Ann. Rev. Immunol.* 3:397 (1985). These include experimental allergic encephalomyelitis, and an autoimmune form of diabetes which develops in the BB rat strain. Similarly, cyclosporin A has been applied in the clinical setting, and used to treat patients with posterior uveitis. Similarly, it has been used to treat type-1 diabetes mellitus in humans. Despite these results, however, cyclosporin A has side effects which has limited its use in the clinical setting. In addition to cyclosporin A, other immunosuppressive drugs have been shown to have a degree of efficacy when used to treat various autoimmune disease. For example, corticosteroids are often used to treat rheumatoid arthritis. Hereto, however, corticosteroids are by no means a cure, but rather provide temporary relief, all-be-it with severe toxic side effects.


#### Summary of the Invention

An object of the invention is to provide immunosuppressive compounds that are useful in treating patients suffering from diseases associated with hyperactive immune systems.

Another object of the invention is to provide analogues or derivatives of succinylacetone that have hitherto unknown immunosuppressive activity when applied to the treatment of graft versus host disease, or autoimmune diseases.

A third object of the invention is to provide derivatives of succinylacetone that are maintained in a patient's circulation for longer times than succinylacetone.

A fourth object of the invention is the description of immunosuppressive compounds that have the formula:



5

wherein

$$n = 1-6$$

$$R = \begin{array}{c} \text{O} & \text{O} \\ || & || \\ \text{CH}_3, \text{CF}_3, -\text{CO}_2\text{R}^{\text{v}}, -\text{CH}, \text{or } -\text{CCH}_3 \end{array}$$

10

$$R^1, R^2 = \begin{array}{c} \text{O} \\ || \\ \text{H}, \text{F}, \text{CH}_3, \text{or } \text{CH}_2\text{CH}_2\text{COR}^{\text{v}} \end{array}$$

15

$$\begin{array}{c} \text{O} & \text{O} \\ || & || \\ R^{\text{m}} = \text{H}, -\text{CO}_2\text{R}^{\text{v}}, -\text{P}(\text{OR}^{\text{v}})_2, \text{CNHR}^{\text{v}}, \text{or tetrazolyl} \\ R^{\text{v}} = \text{H}, \text{or alkyl} \end{array}$$

A further object of the instant invention is to describe methods whereby derivatives of succinylacetone can be administered to patients in effective amounts to control or eliminate graft host disease or various autoimmune diseases.

Other objects and advantages of the present invention will become apparent upon a reading of the detailed description below.

#### Brief Description of the Tables

**Table 1** presents data showing the effects of succinylacetyl-proline derivatized polyethylene glycol 4000 on IL-2 and IFN- $\gamma$  production, as well as the incorporation of tritiated thymidine into human lymphocytes.

25 **Table 2** shows the effect of succinylacetyl-proline derivatized with polyethylene glycol 4000 in a phytohemagglutinin assay.

**Table 3** shows the effect of succinylacetone methyl-ester on the production of IL-2 and IFN- $\gamma$ , and the incorporation of tritiated thymidine in a mixed lymphocyte reaction.

5 -

Table 4 shows the effect of methyl 4-acetyl-5-oxohexanoate on the production of IL-2 and IFN- $\gamma$ , and the 13 human lymphoid cells in a mixed lymphocyte reaction.

Table 5 shows the effect of succinylacetone methyl ester and methyl 4 acetyl-5-oxohexanoate in a phytohemagglutinin assay.

5      Table 6 shows the effect of succinylacetone methyl ester on the incorporation of tritiated thymidine by human lymphoid cells in a secondary mixed lymphocyte reaction.

10     Table 7 shows the effect of methyl 4-acetyl-5-oxohexanoate on the incorporation of tritiated thymidine by human lymphoid cells in a secondary mixed lymphocyte reaction.

Table 8 shows the effect of succinylacetone methyl ester on the viability of peripheral blood lymphocytes, with, or without stimulation by phytohemagglutinin.

Table 9 shows the effect of methyl 4-acetyl-5-oxohexanoate on the viability of peripheral blood lymphocytes, with, or without stimulation by phytohemagglutinin.

15     Table 10 shows the effects of succinylacetone and derivatives in a adjuvant induced arthritis animal model system.

Figure 1 shows analogues and derivatives of succinylacetone.

Figure 2 shows the Sephadex G-50 chromatographic separation of succinylacetyl-proline-PEG.


20     Figure 3 shows the absorbance spectra of fractions 15-34 from the Sephadex G-50 column.

Figure 4 shows the absorbance spectrum of PEG-4000 NH<sub>2</sub>.

#### Description of the Invention

The present invention describes several novel immunosuppressive molecules that 25 are analogues or derivatives of succinylacetone (SA).

Most of the compounds can be described by the following formula:



5 wherein

$$n = 1-6$$

$$R = \text{CH}_3, \text{CF}_3, -\text{CO}_2\text{R}^{\text{IV}}, -\text{CH}, \text{or } -\text{CCH}_3$$

$$10 \quad R', R'' = \text{H, F, CH}_3, \text{ or } \text{CH}_2\text{CH}_2\text{COR}^n$$


$$R^n = \text{H, } -\text{CO}_2\text{R}^{\text{IV}}, -\text{P}(\text{OR}^{\text{IV}})_2, \text{CNHR}^{\text{IV}}, \text{or tetrazolyl}$$

$$R^{\text{IV}} = \text{H, or alkyl}$$

Specific examples of preferred embodiments of the subject immunosuppressive  
15 compounds are shown in Figure 1, along with the structure of succinylacetone.

Figure 1


Succinyl Acetone (SA)



Methyl ester-SA



Methyl 4 acetyl-5-oxohexanoate



7 -

Figure 1 Continued












Figure 1 Continued


SA-hexylamide




6-hydroxy-4-oxo heptanoic acid derivative




4-hydroxy-4-oxo heptanoic acid derivatives




## 5 4,6-dioxo 7,7,7-trifluoro heptanoic acids




4,6-dioxo 5,5-difluoro heptanoic acid



4,6-dioxo 5,5-dimethyl heptanoic acid



4,6-dioxohexanoic acid derivatives



4,6-dioxopimelic acid derivatives





Figure 1 Continued


4,6,8-trioxononanoic acid derivatives




3,5-dioxohexanoic phosphonic acid derivatives




5-(3,5-dioxohexyl) tetrazole



5 4,6-dioxoheptyl alcohol and its phosphate ester




4,4-diacyetyl pimelic acid derivatives




N,N-diacyetyl β-alanine



N,N-diacetyl- $\gamma$ -amino-butyric acid



Methyl 4-acetyl-5-oxohexanoate



5

The immunosuppressive properties of the instant molecules can be described both as to *in vitro* and *in vivo* efficacy in experimental systems. It is important to point out that the results obtained from the *in vitro* systems are directly predictive of the *in vivo* immunosuppressive properties of the derivatives of succinylacetone described herein. The *in vitro* mixed lymphocyte assay described below is presently employed in the clinical setting as an indicator of histocompatibility, and is premised

on the transformation of resting genetically dissimilar lymphocytes into cells which synthesize DNA and undergo proliferation. It has been demonstrated that incompatibility at the major histocompatibility complex is mainly responsible for this phenomenon.

5       A second assay widely used to study immune responsiveness is mitogenic stimulation of thymocytes with antigenic substances of plant origin. The most widely used plant molecule is phytohemagglutinin (PHA). Although PHA stimulates DNA synthesis nonspecifically in a large number of lymphocytes, unlike true antigenic stimulation which causes mitogenesis of sub-populations of lymphocytes, the  
10      susceptibility of a patient's lymphocytes to PHA stimulation has been shown to correlate with the overall immune responsiveness of the patient.

Thus, it will be appreciated as to both the mixed lymphocyte and PHA assay that they are valuable for identifying immune suppressive molecules in vitro, and that the results obtained therefrom are predictive of their in vivo effectiveness.


15      The following definitions will assist in understanding the invention.

Derivatives of succinylacetone, in addition to those shown in Figure 1, may include succinylacetone conjugated to polyethylene glycol (PEG), polypropylene glycol (PPG) or other polymer molecules known to extend the in vivo circulation time of medicaments.


20      The polymer need not have any particular molecular weight, but it is preferred that the molecular weight be between about 300 and 100,000, more preferably between 350 and 40,000, depending, for example, on the particular succinylacetone derivative.

Preferably the PEG homopolymer is unsubstituted, but it may also be substituted at one end with an alkyl group. Preferably the alkyl group is a C<sub>1</sub>-C<sub>4</sub> alkyl group, and most preferably a methyl group. Most preferably, the polymer is an unsubstituted homopolymer of PEG, a monomethyl-substituted homopolymer of PEG or polyoxyethylated glycerol, and has a molecular weight of about 350 to 40,000.

Pegylated proline succinylacetone (succinylacetyl-proline-PEG) is preferred in the invention and has the structure:




Succinylacetyl-proline-PEG, the methyl ester derivative, and glutarylacetone, and adipoylacetone, were synthesized as described in detail below. Methyl 4 acetyl-5-oxohexanoate was purchased from Aldrich Chemical Corp. The synthesis of



is described in Journal of Labelled Compounds and Radiopharmaceuticals, 1985, 10 22(9):869-881, and in U.S. Patent No. 4,011,321.

The synthesis of



and 4,4-diacyl pimelic acid are described in Japanese Patent No. 57/203030, and in Australian Journal of Chemistry, 1967, 20:123-130, respectively.

Also, N, N-diacyl β-alanine and 6-hydroxy 4-keto heptanoic acid methyl ester are described in the Journal of Medicinal Chemistry, 1985, 28:9-12 and in Journal of Organic Chemistry, 1988, 53:4893, respectively. All of the above publications are hereby incorporated by reference in their entireties.

Furthermore, the following compounds may be synthesized as described below:

**Succinyl Trifluoroacetone Methyl Ester**

20 **Succinyl Trifluoroacetone**

**Acetoacetyl Methyl Benzoate**

**2-Acetoacetyl Benzoic Acid**

**Synthesis of 3,5-Dioxohexylacyanide**

**Synthesis of 5-(3,5-Dioxohexyl) Tetrazole**

Synthesis of Beta-Keto *t*-Butyldimethylsilyl Enol Esters of SA Methyl Ester

Synthesis of Beta-Keto Isopropyl Enol Esters of SA Methyl Ester

Synthesis of Beta-Hydroxy Keto Derivatives of SA Methyl Ester

Synthesis of 4,6,8-Trioxo Methyl Nonanoate

5       Derivatives of succinylacetone were tested for immunosuppressive activity in several different types of assay systems. The first consisted of measuring the amounts of interleukin-2 (IL-2), and interferon- $\gamma$  (IFN- $\gamma$ ) produced by human lymphoid cells in a mixed lymphocyte reaction. Low levels of these molecules in the reaction mixture indicate that the immune system is being suppressed by the subject succinylacetone

10      derivatives.

IL-2 and IFN- $\gamma$  levels were determined as follows:

IL-2 was measured by enumerating the number of viable HT-2 cells found after an 18-24 hours period. HT-2 cells are a mouse IL-2 dependent cell line which die in the absence of IL-2. The assay is described by Gillis et al., J. of Immunol. 120:2027 (1978).

15      IFN- $\gamma$  was determined by measuring the amount of protection conveyed on human WISH cells against the cytopathic effects of encephalomyocarditis virus (EMC). This assay is described by I. A. Braude, J. of Immunol. Methods 63:237 (1983). Both publications are hereby incorporated by reference.

20      The mixed lymphocyte reaction assay can be carried out by techniques well known to those skilled in the art. L. Hudson and F. C. Huy, Practical Immunology, p. 260, Blackwell Scientific Publications (1976). Briefly this consists of isolating lymphocytes from human peripheral blood by standard density gradient centrifugation techniques from two separate individuals. Approximately  $2 \times 10^5$  lymphocytes of each 25 individual are combined to yield a total of  $4 \times 10^5$  lymphocytes per culture. All procedures are carried out under sterile conditions, and the lymphocytes are isolated and kept in physiologically compatible solutions. To the mixture of lymphocytes is added a desired amount of an appropriate succinylacetone derivative, and after different times an aliquot of the mixture is removed and assayed for IL-2 or IFN- $\gamma$ , or  $^3\text{H}$ -T is 30 measured.

Succinylacetyl-Proline-NH-PEG

Table 1 shows that there is a considerable diminution in the amount of IL-2 and IFN- $\gamma$  produced as a function of the concentration of succinylacetyl-proline-NH-PEG. It is worth noting that when compared to cell culture media, Roswell Park

5 Memorial Institute media (RPMI), not containing succinylacetyl-proline-NH-PEG, that there is more than about a three fold decrease in the amount of either IL-2, or IFN- $\gamma$ . It will be appreciated that Table 1 presents the results from two separate experiments.

Table 1 also presents a control experiment wherein the effects of PEG-4,000-  
10 NH<sub>2</sub> on IL-2 and IFN- $\gamma$  production is shown. Although PEG-4000-NH<sub>2</sub> does inhibit the production of these molecules, inhibition, however, is well below that observed for succinylacetyl-proline-NH-PEG.

As mentioned above, one measure of an immune response as reflected in a mixed lymphocyte assay is the stimulation of DNA synthesis, and a concomitant  
15 increase in cell number. Thus, to further ascertain the immunosuppressive activity of succinylacetyl-proline-NH-PEG, its effect on inhibition of thymocyte growth, as detected by uptake of tritiated thymidine, was assayed. Table 1 shows the results. A 50% reduction in thymidine uptake is observed at a concentration of about 625  $\mu$ M  
20 succinylacetyl-proline-PEG. This inhibition should be compared to about 2% observed for PEG-4000-NH<sub>2</sub>.

TABLE I  
Succinylacetyl-proline-NH-PEG vs PEG-4000-NH<sub>2</sub>

	SAMPLE	IL-2 Exp.I	IFN- $\gamma$ Exp.I cpm	IFN- $\gamma$ Exp.II cpm	CPM(% Exp.I %Inhib.)	INHIBITION	
	SA-pro-NH-PEG	Exp.II	Exp.II	Exp.II	Exp.II	EXP.II	
5	10mM	<7	<6	<945	<1125	26 99.95	127 99.7
	5.0mM	<7	<6	<945	<1125	1162 97.9	182 99.6
	2.5mM	<7	<6	<945	<1125	598 98.9	1467 96.9
	1.25mM	<7	<6	4980	<1125	9729 82.7	8787 81.3
10	625mM	<7	<6	5603	1041	31490 38.5	25471 45.8
	313mM	<7	<6	4150	2802	41599 18.8	34570 26.5
	156mM	8	8	4980	2179	44129 21.7	29907 36.4
	78mM	<7	5	5603	2179	47326 16.0	33977 27.7
	RPMI media	24	19	2802	1868	56358 ---	47016 ---
15	PEG-4000-NH <sub>2</sub>						
	10mM	8	10	1972	1556	18545 70.7	23733 43.1
	5.0mM	10	10	3113	1868	32003 49.5	28961 30.5
	2.5mM	15	17	3113	1868	50295 20.6	33330 20.1
	1.25mM	14	17	3424	1972	56850 10.2	45587 9.3
20	625μM	19	17	3113	1868	59571 5.9	42578 2.1
	313μM	20	26	5188	1868	56774 10.3	42970 3.1
	156μM	21	41	4047	1547	67188 6.1	36185 13.2
	78μM	18	23	3424	1688	61969 2.1	47187 -13.2
	RPMI media	18	25	1972	1778	63327 ---	41694 ----

Table 2 shows the effect of succinylacetonyl-proline-NH-PEG in a phytohaemagglutinin assay. The procedure for carrying out the phytohaemagglutinin assay is also well known to those skilled in the art. Briefly, it consists of isolating human lymphocytes as described above, and incubating about  $1.0 \times 10^6$  cells per ml in a suitable physiological solution with phytohaemagglutinin, and the appropriate concentration of succinylacetone-proline-NH-PEG. Tritiated thymidine is added 48 hours later and allowed to incubate for twenty-four hours before the cells are counted. Table 2 shows that there is more than an 80% inhibition of tritiated thymidine uptake at a concentration of 8.3 mM, and that this inhibition decreases rapidly to about 10% at a concentration of 925  $\mu$ M. In a second phytohemagglutinin assay, also shown in Table 2, wherein lymphocytes isolated from a second individual were tested, it is apparent that the level of inhibition is even greater. Approximately 95% inhibition is observed at a concentration of 8.3 mM succinylacetonyl-proline-NH-PEG, and this diminishes to 38.7% at a concentration of 925  $\mu$ M.

15

TABLE IISuccinylacetonyl-proline-NH-PEG-4000 in PHA Assay**SAMPLE**

		CPM $\pm$ SD		% Inhib.	CPM $\pm$ SD		% Inhib.
20	8.3mM	8386	1242	(83.6)	2748	786	(95.2)
	2.8mM	35839	2352	(29.9)	23869	1410	(59.0)
	925 $\mu$ M	45744	1129	(10.6)	35678	12393	(38.7)
	309 $\mu$ M	49754	4294		47690	9003	(7.2)
	102 $\mu$ M	49805	12018		40562	9677	
25	34 $\mu$ M	51149	6031		30116	720	
	11.3 $\mu$ M	50680	2000		34898	3607	
<b>RPMM MEDIA</b>		51149	5542		58159	4858	
<b>PHA +</b>		47165	1524		51378	8890	
<b>PHA -</b>		126	56		135	64	

Succinylacetone Methyl Ester

A second derivative of succinylacetone which was shown to have considerable immunosuppressive activity is succinylacetone methyl ester. Table 3 shows the effects of varying the concentration of succinylacetone methyl ester on the production of IL-2 or IFN- $\gamma$  in a mixed lymphocyte reaction. The results from duplicate experiments are shown. The concentration of succinylacetone methyl ester that inhibits the production of both of these substances by about 50% is 733  $\mu$ M.

Table 3 also shows the inhibition of tritiated thymidine uptake in a primary mixed lymphocyte reaction as a function of succinylacetone methyl ester concentration. 10 Duplicate experiments are also shown. The concentration that inhibits tritiated thymidine uptake by one-half is approximately 733  $\mu$ M. Succinylacetone methyl ester was also tested in a phytohaemagglutination assay to further determine the potency of its immunosuppressive activity, and to ascertain whether this assay correlates with the results obtained in the primary mixed lymphocyte reaction assay. Table 5 shows two 15 mixed lymphocyte assays conducted in duplicate using the lymphoid cells from two individuals. The amount of succinylacetone methyl ester that displays a 50% inhibition of phytohaemagglutination stimulation is between 103-309  $\mu$ M in one assay, and about 103  $\mu$ M in the second assay.

TABLE IIIMethyl Ester SA-1° MLR

SAMPLE	IL-2		IFN- $\gamma$		CPM $\pm$ SD			
	ExpI	ExpII	ExpI	ExpII	ExpI	ExpII		
5								
20mM	<6	<8	<630	<375	164	28	90	38
6.7mM	<6	<8	<630	<375	89	16	126	2
2.2mM	<6	<8	788	<375	3185	486	33497	
733 $\mu$ M	14	23	1890	688	30535	3068	40700	10026
10	244 $\mu$ M	19	28	1575	938	66159	2795	78306
	81 $\mu$ M	24	28	1628	1094	80182	9420	87595
	27 $\mu$ M	25	34	2713	1032	75211	2332	97879
	9 $\mu$ M	28	38	1860	1000	87101	7114	110425
	3 $\mu$ M	41	34	2558	1313	81740	114428	1060
15	RPMI	30	54	2325	1313	84707	299	109628
								9886

Methyl 4 Acetyl-5-Oxohexanoate

An analogue of succinylacetone was shown to have immunosuppressive activity, and this is methyl 4-acetyl-5-oxohexanoate. Table 4 summarizes its immunosuppressive effects in a primary mixed lymphocyte reaction assay where the parameters measured were IL-2 or IFN- $\gamma$  production. Approximately 2.2 mM methyl 4 acetyl-5-oxohexanoate causes a 50% reduction in the production of either of these molecules. Table 4 also shows the effects of these compounds on the incorporation of tritiated thymidine in a mixed lymphocyte assay. Again, it was observed that the concentration of methyl 4-acetyl-5-oxohexanoate that causes a 50% inhibition in thymidine uptake is about 2.2 mM.

TABLE IV  
Methyl 4-Acetyl-5-Oxohexanoate-1 MLR

Sample	ExpI			ExpII				
	ExpI	ExpII	ExpI	ExpII	ExpI	ExpII		
20mM	<6	<12	<285	<469	163	2	109	3
5 6.7mM	<6	<12	<285	<469	135	2	21280	2448
2.2mM	9	35	285	703	29389	2138	84363	4217
733μM	17	70	570	1172	67787	3233	113732	5345
244μM	17	52	998	1953	48284	-----	122672	21280
81μM	42	70	1313	1560	81881	2876	113054	3782
10 27μM	30	52	1260	1248	77634	8627	112463	7009
9μM	46	85	1260	1248	77627	6627	117109	3074
3μM	29	70	1260	1144	74259	4938	114713	2136
RPMI MEDIA	23	77	1260	1248	77397	81	114230	1186

15        Methyl 4-acetyl-5-oxohexanoate was also tested in a phytohemagglutination assay, and these results are shown in Table 5. Two assays were conducted using lymphoid cells from two individuals. In both assays the concentration of methyl 4-acetyl-5-oxohexanoate that caused about a 50% inhibition in phytohaemagglutination stimulation was about 309 μM.

TABLE VPHA - Stimulation of Succinylacetone Methyl Ester And  
Methyl 4-Acetyl-5-Oxohexanoate

	Succinyl- Acetone Methyl Ester	EXP. I		EXP. II		Methyl 4- Acetyl-5- Oxohexa- noate		EXP. I		EXP. II	
		EXP. I		EXP. II		Methyl 4- Acetyl-5- Oxohexa- noate		EXP. I		EXP. II	
		cpm	±SD	cpm	±SD	cpm	±SD	cpm	±SD	cpm	±SD
10	25mM	113	20	112	33	25 mM	200	108	200	55	
	83mM	79	29	107	53	83 mM	192	33	156	28	
	2.8mM	126	38	65	12	2.8mM	116	41	717	91	
	926μM	565	36	6949,234.	12	926μM	2276	154	5600	1195	
15	309μM	5927	124	5292	891	309μM	14098	92	19713	3109	
	103μM	17595	2625	17733	6322	103μM	18677	1409	30569	3168	
	34μM	16549	1394	28614	5959	34μM	19399	547	34006	1101	
	11μM	18100	862	28645	4692	11μM	19401	1995	33417	7177	
	3.8μM	20292	1643	37936	2487	3.8μM	19888	3900	33799	1633	
20	RPMI MEDIA	21587	89	36957	3908			18405	1777	38185	6925

Secondary Mixed Lymphocyte Assays

In addition to testing the immunosuppressive activities of succinylacetone derivatives in a primary mixed lymphocyte reaction, or a phytohemagglutinin stimulation assay, two of the derivatives, succinylacetone methyl ester and methyl 4-acetyl-5-oxohexanoate, were tested in a secondary mixed lymphocyte reaction assay. The secondary mixed lymphocyte assays differs from the primary mixed lymphocyte reaction assays in that they employ many more primed responder cells that are responsive to the primary stimulating cells. The presence of such responsive cells is a reflection of immunological memory in an ongoing immunological response. The protocol for carrying out a secondary mixed lymphocyte assay involves performing a

primary lymphocyte assay as described above, and recovering viable cells about 9-10 days after the primary mixed lymphocyte reaction exhibits little or no cell proliferation. Generally between 10% to 50% of the original input cells are recovered in viable condition. These cells are then used in the secondary mixed lymphocyte reaction. It is worth noting that because a secondary mixed lymphocyte reaction is greatly enriched for responsive cells, fewer cells can be used in the secondary assay.

The procedure for carrying out a secondary mixed lymphocyte reaction is described by T. Meoen, Immunological Methods, Eds I. Lefkoivits and B. Pernis, 10 Economic Press, New York (1979). It will be appreciated that described therein is a method for carrying out secondary lymphocyte reactions using mouse cells, however such methods are generally applicable to performing secondary mixed lymphocyte reactions using human cells with modifications that are well known to those skilled in the art. Tables 7 and 8 show immunosuppressive effects of succinylacetone methyl ester, and methyl 4-acetyl-5-oxohexanoate on the uptake of tritiated thymidine in 15 secondary mixed lymphocyte assay. The assays were conducted in duplicate involving lymphoid cells isolated from two individuals. It is important to note that the immunosuppressive effects of both chemicals are similar to those observed in the primary mixed lymphocyte reaction assay, and therefore are correlative of their suppressive effects described in that system. For succinylacetone methyl ester or 20 methyl 4-acetyl-5-oxohexanoate the concentration that causes about a 50% reduction in tritiated thymidine uptake is between about 2.2 mM and 740 µM.

TABLE VISuccinylacetone Methyl Ester 2°-MLR

	<b>Sample</b>	<u>Exp I</u>			<u>Exp II</u>		
		<b>CPM</b>	<b>±SD</b>	<b>% Inhib.</b>	<b>CPM</b>	<b>±SD</b>	<b>% inhib.</b>
5	<b>20mM</b>	64	29	(99.9)	87	13	(99.9)
	<b>6.7mM</b>	51	18	(9.99)	62	4	(9.99)
	<b>2.2mM</b>	11778	2205	(85.4)	29851	6242	(68.0)
	<b>740μM</b>	67456	--	(16.3)	85447	12061	(8.5)
	<b>247μM</b>	87337	479		125345	35225	
10	<b>MEDIA</b>	80578	8523		93241	9086	
	<b>PBL</b> <b>EBV</b>	11658 196	122 35		50760 153	1581 62	

15  
TABLE VII  
Methyl 4-Acetyl-5-Oxohexanoate  
2°-MLR

	<b>Sample</b>	<u>Exp I</u>			<u>Exp II</u>		
		<b>CPM</b>	<b>±SD</b>	<b>% Inhib.</b>	<b>CPM</b>	<b>±SD</b>	<b>% inhib.</b>
20	<b>20mM</b>	76	9	(9.99)	134	51	(9.99)
	<b>6.7mM</b>	112	35	(9.99)	4402	2242	(95.3)
	<b>2.2mM</b>	1995	--	(97.5)	43264	10237	(53.7)
	<b>740μM</b>	61568	8943	(23.6)	88958	2804	(4.8)
	<b>247μM</b>	73805	13480		86893	4332	
25	<b>MEDIA</b>	80578	8523		93421	9086	
	<b>PBL</b> <b>EBV</b>	11658 196	122 35		50760 153	1581 62	

### 5 Viability Testing

In order to insure that the immunosuppressive effect of the succinylacetone derivatives was not being caused by generalized cytotoxicity, the effect of succinylacetone methyl ester, and methyl 4-acetyl-5-oxohexanoate on the viability of peripheral blood lymphocytes in a phytohaemagglutination stimulation assay was determined. Viability was determined using the trypan blue exclusion method well known in the art. Tables 8 and 9 show the results for succinylacetone methyl ester and methyl 4-acetyl-5-oxohexanoate, respectively. The assays were conducted in duplicate wherein peripheral blood lymphocytes were isolated from two separate individuals, and then treated with or without phytohemagglutinin in the presence of various concentrations of the appropriate succinylacetone derivative. Table 8 shows there is little viability at a concentration of about 6.7 mM succinylacetone methyl ester. However, viability is greatly increased, and is nearly 100%, at a concentration ranging between 2.2 mM and 733 µM. These concentrations are those which were shown to be effective in the immunosuppressive assays described above.

Surprisingly, methyl 4-acetyl-5-oxohexanoate exhibits no toxicity even at concentrations as high as 20 mM (Table IX).

TABLE VIII

Viability Methyl Ester SA

		(-) PHA		(+)-PHA		(-) PHA		(+)-PHA	
		Sample*	% Via	Cells/ml	% Via	Cells/ml	% Via	Cells/ml	% Via
		20mM	NO	0		ND	0	ND	0
		6.7mM	0.15	7		0.13	8	0.23	4
		2.2mM	0.36	94		0.3	89	0.42	94
		733μM	0.34	96		0.4	90	0.48	95
5		244μM	0.35	100		0.38	97	0.46	98
		81μM	0.37	100		0.4	96	0.53	100
		27μM	0.60	100		0.37	97	0.43	100
		9μM	0.36	100		0.32	100	0.51	100
		3μM	0.60	100		0.48	100	0.5	100
10		MEDIA *X10 <sup>6</sup>	0.5	100		0.52	98	0.4	100
15								0.48	100

TABLE IXPBL Viability Methyl 4-Acetyl-5-Oxohexanoate

	Sample*	(-) PHA		(+)-PHA		(-) PHA		(+)-PHA	
		Cells/ml	% Via % Via	Cells/ml	% Via	Cells/ml	% Via	Cells/ml	
5	20mM	0.5	100	0.49	100	0.5	100	0.55	100
	6.7mM	0.57	100	0.46	100	0.6	100	0.50	100
	2.2mM	0.57	100	0.49	100	0.54	100	0.50	100
10	733μM	0.37	100	0.38	100	0.41	100	0.40	100
	244μM	0.40	100	0.44	100	0.5	100	0.54	100
	81μM	0.42	100	0.38	100	0.46	100	0.40	100
	27μM	0.44	100	0.46	100	0.50	100	0.50	100
	9μM	0.55	100	0.47	100	0.52	100	0.50	100
15	3μM	0.39	100	0.45	100	0.44	100	0.40	100
	MEDIA	0.44	100	0.38	100	0.43	100	0.48	100
	*X10 <sup>6</sup>								

In Vivo Results

The immunosuppressive effects of two of the derivatives of succinylacetone were determined in a rheumatoid arthritis experimental animal model system, and compared to the effects of succinylacetone. The derivatives were succinylacetone methyl ester and methyl 4-acetyl-5-oxohexanoate. The experimental model system was adjuvant induced arthritis in rats, and the protocol is described by J. Holoshitz, et al., Science 219:56 (1983), or by B. Waksman and C. Wennersten, Int. Arch. Allergy Appl. Immunol. 23:129 (1963). Induction of the disease can be caused by a single injection, generally intradermally, of a suspension of killed Mycobacterium tuberculosis in complete Freund's adjuvant (CFA). The route of injection can vary, but in the instant invention rats were injected at the base of the tail with an adjuvant mixture.

The procedure for testing the effects of succinylacetone methyl ester and methyl 4-acetyl-5-oxohexanoate consisted of intradermally injecting killed Mycobacterium tuberculosis in CFA followed by either immediate treatment every other day with the derivatives or subsequent administration starting at 4 or 14 days 5 later. The derivatives were administered intraarticularly into the right paw at concentrations of 325 µg, 150 µg, and 560 µg per kilogram of body weight for succinylacetone, succinylacetone methyl ester, and 4-acetyl-5-oxohexanoate, respectively.

Table 10 shows the effects of succinylacetone methyl ester and methyl 4-  
10 acetyl-5-oxohexanoate along with succinylacetone. Experiment I consisted of administering Mycobacterium in CFA and the appropriate compound on the same day, and every other day until day 24. Experiments II and III were similarly performed with the difference that succinylacetone or the derivatives were administered every other day starting at 4 or 14 days respectively, after  
15 Mycobacterium/CFA administration until day 24. At the appropriate times, 14, 16, 18, 20 and 22 days after injection of Mycobacterium CFA, an overall arthritis score was obtained as described by J. Holoskitz above. It is apparent that the methyl ester derivative is most effective when it is administered 14 days after induction of the disease, (Exp. III, Table X). Moreover, succinylacetone is also effective when  
20 administered 14 days subsequent to injection of Mycobacterium tuberculosis plus CFA. In contrast, 4 acetyl-5-oxohexanoate is apparently most active when administered every other day from day 4 to day 24.

TABLE X

COMPOUND  
TIME (DAYS)

		<b>14</b>	<b>16</b>	<b>18</b>	<b>20</b>	<b>22</b>	<b>24</b>	<b>26</b>
Succinylacetone	Exp. I	0.6 ± 1.3	0.8 ± 1.8	1.4 ± 2.6	3 ± 5	3.8 ± 5	4 ± 3.9	5 ± 4.3
	Exp. II	3.2 ± 3.8	3.2 ± 3.8	4.8 ± 3.6	7 ± 2.3	6.2 ± 2.4	6 ± 2.7	7.8 ± 3
	Exp. III	2.0 ± 3.9	2.0 ± 3.9	2.0 ± 2.9	2.4 ± 2.9	4.0 ± 3.7	2.8 ± 2.8	3.4 ± 2.7
Succinylacetone Methyl Ester	Exp. I	2.4 ± 2.5	2.8 ± 2.4	3.4 ± 1.9	6.4 ± 3.6	6.8 ± 4.0	7.2 ± 4.1	6.2 ± 3.7
	Exp. II	1.6 ± 2.6	2 ± 2.8	3.2 ± 4.0	4.0 ± 4.6	4.8 ± 4.1	4.8 ± 4.1	5.6 ± 4.7
	Exp. III	1.2 ± 1.8	1.4 ± 1.3	1.4 ± 2.2	4.8 ± 3.8	4.4 ± 3.6	4.4 ± 3.6	3.0 ± 3.3
<b>Methyl 4 Acetyl-5 oxo</b>	<b>Exp. I</b>	<b>3.2 ± 2.2</b>	<b>3.4 ± 2.2</b>	<b>5.0 ± 3.2</b>	<b>7.0 ± 4.0</b>	<b>8.2 ± 4.9</b>	<b>7.2 ± 4.2</b>	<b>7.2 ± 4.2</b>
<b>Hexanoate</b>	<b>Exp. II</b>	<b>1.0 ± 1.4</b>	<b>2.2 ± 2.5</b>	<b>1.8 ± 1.8</b>	<b>2.2 ± 2.0</b>	<b>5.0 ± 3.5</b>	<b>3.4 ± 3.6</b>	<b>4.0 ± 3.7</b>
	<b>Exp. III</b>	<b>2.0 ± 2.0</b>	<b>2.4 ± 1.5</b>	<b>3.4 ± 2.6</b>	<b>5.6 ± 2.7</b>	<b>7.4 ± 4.8</b>	<b>7.4 ± 5.3</b>	<b>7.4 ± 5.3</b>

### Synthesis

A number of succinylacetone derivatives described herein were produced as follows. For preparation of succinylacetyl-proline-NH-PEG, an attempt was made first to generate an active ester of succinylacetone. Succinylacetone was dissolved in 5 an aprotic organic solvent, (preferably dimethyl formamide, chloroform, or dichloromethane, among others), and converted to an ester by addition of an equimolar amount of an appropriate condensing agent, such as a carbodiimide, (preferably dicyclohexyl carbodiimide, or 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide (EDAC)), and a slight molar excess of an appropriate ester forming 10 alcohol, (preferably p-nitrophenol, 4-hydroxyl-3-nitro-benzene sulfonate, or N-hydroxysuccinimide, among others). It was expected that this reaction would produce an active ester from the alcohol and succinylacetone. However, subsequent experiments revealed that an enol lactone is, indeed, an intermediate in the reaction, and this was confirmed by subsequent NMR analyses of succinylacetone reacted with 15 carbodiimide in the absence of an alcohol. Enol-lactone, in turn, reacts with both primary and secondary amines to produce the desired amides. Concomitant with the formation of the enol-lactone is the formation of urea from the carbodiimide.

When succinylacetone is treated as described-above with a secondary amine such as proline, the product formed is succinylacetyl-proline. Succinylacetyl-proline can be converted to succinylacetyl-proline-NH-PEG by combining it with a condensing agent, in the presence of a suitable ester forming alcohol to form an active ester of the carboxylic acid group of proline. The preferred alcohol is p-nitrophenol, although other alcohols such as, for example, N-hydroxysuccinimide, 4-hydroxy-3-nitro-benzenesulfonate, among others may be used. The final step in this 25 reaction sequence is to react the succinylacetyl-prolyl-nitrophenyl active ester with PEG-NH<sub>2</sub>, which results in the desired product, succinylacetyl-proline-NH-PEG.

The succinylacetone active esters, or other activated species, formed in the step described above are also reactive with primary amines, which thus affords a synthetic route towards realizing succinylacetone PEG, which was employed as a 30 control in a number of the experiments. Succinylacetyl-NH-PEG is realized by combining succinylacetone active species, probably the enol-lactone, or other activated species with PEG-NH<sub>2</sub>, which produces succinylacetyl-NH-PEG.

Succinylacetyl-Proline-NH-PEGSuccinylacetyl-Proline

In more detail, succinylacetyl-proline-NH-PEG was synthesized by first generating succinylacetyl-proline. This consisted of dissolving 1 gm of 5 succinylacetone (6.3 mmole) and 1.6 gm (6.6 mmole) of 1-hydroxyl-2-nitro-benzene-4-sulfonic acid in 10 ml dimethyl formamide. Next a suitable condensing agent was added, particularly useful is dicyclohexylcarbodiimide. About 1.6 g of 10 dicyclohexylcarbodiimide (6.3 mmole) was added to the mixture. After the reaction was stirred at room temperature for a short time (10 minutes), dicyclohexylurea began to precipitate. Dicyclohexylurea was removed from the reaction mixture by filtering, followed by adding the filtrate to a dimethyl formamide solution containing 0.74 g proline (6.3 mmole). The combined solutions were stirred overnight.

The reaction was diluted with an equal volume of water, and extracted ten times with 10 ml of ethyl acetate. The combined organic extracts were dried over 15 MgSO<sub>4</sub>, filtered to remove MgSO<sub>4</sub> hydrate, and concentrated on a rotary evaporator to produce a thick slurry. Succinylacetone was separated from succinylacetyl-proline using a 4 mm Chromatotron spinning plate silica gel chromatogram equilibrated with a solvent consisting of chloroform:acetic acid in the ratio of 90:10. Succinylacetone eluted at the solvent front. Succinylacetyl-proline eluted with a more polar solvent 20 consisting of chloroform:acetic acid:methanol in the ratio of 90:10:3. Those fractions containing succinylacetyl-proline were pooled, concentrated with a rotary evaporator and the remaining acetic acid solution diluted with water, followed by quick freezing and lyophilization. The final product was a yellow oil.

In a thin layer chromatography plate developed in 90:10 chloroform:acetic acid 25 succinylacetone showed an R<sub>f</sub> of 0.78 while the product succinylacetyl-proline has an R<sub>f</sub> of 0.23, and proline remains at the origin.

Succinylacetyl-proline-NH-PEG

Succinylacetyl-proline was converted to succinylacetyl-proline-NH-PEG by adding succinylacetyl-proline to a condensing agent in the presence of p-nitrophenol in chloroform. The reaction was carried out in 10 ml of chloroform by 30 adding 0.55 g (4.0 mmole) of p-nitrophenol to 0.64 g (3.9 mmole) of succinylacetone-proline. Next, 0.80 g (3.3 mmole) of the condensing agent,

dicyclohexylcarbodiimide was added. The latter was dissolved in 2 ml chloroform, and added slowly to the mixture with stirring. Within 10 minutes, a white precipitate of dicyclohexylurea formed, and a spectrophotometric determination [L. Aldwin and D.E. Nitecki, 1987, *Anal. Biochem.*, 164:494-501] of the amount of ester present at 5 that time indicated that there was approximately 61.5% ester present. A similar determination two hours later revealed no change in the amount of ester formed. Dicyclohexylurea was removed by filtering the solution, followed by the addition of 0.45 g (1.1 mmole) PEG-4000-NH<sub>2</sub> to the filtrate. The reaction mixture was allowed to stir at room temperature overnight. The product, succinylacetyl-proline-NH-PEG 10 was purified as follows.

The reaction mixture had a granular appearance, and therefore was filtered, followed by removal of the organic solvent with a rotary evaporator. This left a thick oil in the rotary evaporator flask which was not completely soluble in water. It was extracted three times with ethyl ether, to remove impurities which were not 15 water soluble. PEG is completely insoluble in ethyl ether, and therefore succinylacetyl-proline-PEG was expected to remain in the aqueous phase. The aqueous phase was applied to a G-50 Sephadex sizing column (3 cm diameter x 41 cm high) that had previously been equilibrated with distilled water. The column was washed with distilled water and 4 ml fractions collected and monitored 20 spectrophotometrically to produce the elution profile shown in Figure 2. This chromatographic step primarily separates small molecular weight molecules such as succinylacetyl-proline from larger ones such that PEG-4000-NH<sub>2</sub> and succinylacetyl-proline-NH-PEG co-elute. Spectrophotometric analysis of fractions 16-34 from the Sephadex G-50 column revealed that this material absorbs between 25 250-340 nm. This is in contrast to PEG-4000-NH<sub>2</sub> which absorbs in the range of about 210-225 nm. These results are shown in Figures 3 and 4. Figure 3 shows the spectrum of PEG-4000-NH<sub>2</sub>, while Figure 4 shows the spectra of some of the Sephadex G-50 fractions.

Fractions 15-34 were pooled and lyophilized to a white powder. Thin layer 30 chromatography plates developed in 90:10 chloroform:acetic acid indicated that most of the ninhydrin reacting compound remained at the origin. No succinylacetone was detectable on the plate, but trace amounts of succinylacetyl-proline could be seen. This method was used to produce the compounds for the bioassays shown in Table 1.

The mixture was later repurified over a G-50 Sephadex column so that no trace of succinylacetone-proline could be detected on TLC plates. The purer succinylacetone-proline-NH-PEG-4000 was used in the bioassays shown in Table 2.

#### Succinylacetyl-NH-PEG

5       Approximately 0.158 grams (1.0 mMole) of succinylacetone was combined with 1.0 gram of PEG-NH<sub>2</sub> (molecular weight 10K) in 10 ml chloroform. Next 0.206 grams of dicyclohexylcarbodiimide was added in a small amount of chloroform. The reaction was allowed to proceed at room temperature overnight and was shielded from exposure to light. The major by-product of the reaction, dicyclohexylurea, was  
10 removed by filtration, and the slightly yellow filtrate concentrated by rotary evaporation. The remaining oil was dissolved in H<sub>2</sub>O and dialyzed against dilute acetic acid, and subsequently water. After three changes of dilute acetic acid and three changes of water, the contents of the dialysis bag were lyophilized. The white powder was redissolved in distilled water and was chromatographed over a gel  
15 filtration column, Sephadex G-50 (available from Pharmacia Corp.), to remove small molecular weight impurities. Fractions containing succinylacetyl-NH-PEG were identified spectrophotometrically, and shown to contain succinylacetyl-NH-PEG by thin layer chromatography.

#### Succinylacetone Methyl Ester

20       Succinylacetone methyl ester, methyl 4-6-dioxoheptanoate, was synthesized as described by A. R. Battersby, et al., J.C.S. Perkin I, 1981:2786-2792.

#### Glutarylacetone Methyl Ester

Glutarylacetone methyl ester, (methyl 5, 7-dioxohexanoate), was synthesized by reacting a magnesium complex of t-butyl acetoacetate with methyl 4-chloroformyl butyrate. The magnesium complex of t-butyl acetoacetate, in turn, was synthesized as described by Battersby, 1981, J. Chem. Soc., Perkin Transactions I, p.2786-2799. Briefly, methanol (250 mL) was added to a mixture of magnesium shavings (15.91 gm; 654.5 mmole) and 0.5 mL of carbon tetrachloride. The mixture began to reflux as the metal dissolved and a cold water bath was used to control the  
25 reaction. After the metal had completely dissolved in the alcohol, and the mixture  
30

had cooled, t-butyl acetoacetate (106.7 mL; 101.8 gm; 664.2 mmole) was added dropwise over ten minutes. The mixture was refluxed for one hour, cooled, and filtered. The magnesium complex of t-butyl acetoacetate was collected, washed with cold methanol and dried under vacuum.

5 To a suspension of the magnesium complex of t-butyl acetoacetate (75 gm; 353 mmole) in 125 mL of ether was added methyl 4-(chloroformyl) butyrate (54 mL; 64.31 gm; 391 mmole). The addition was made dropwise, with stirring under a reflux condenser. After the addition was complete, the mixture was refluxed for thirty minutes and allowed to cool. To the mixture was added 125 mL of 1.8M  
10 sulfuric acid and the two-phase mixture transferred to a one liter separatory funnel. The aqueous layer was extracted with ether (3X100 mL) and the combined ether extracts were washed with brine (4X50 mL). The ether was evaporated and to the residue was added 300 mg of p-toluenesulfonic acid monohydrate. The mixture was heated to 170°C and evolution of gas monitored with a bubbler. When gas evolution  
15 had subsided, the dark mixture was allowed to cool and 250 mL of ether was added. The solution was transferred to a one liter separatory funnel and extracted with ice-cold 2M sodium hydroxide (100, 50, 25 and 25 mL). The extracts were run directly into ice-cold 1.8M sulfuric acid (250 mL). The acidic suspension was extracted with methylene chloride (3X150 mL). The organic extracts were pooled  
20 and washed with 5% sodium bicarbonate (2X50 mL) and brine (2X50 mL), dried over sodium sulfate, filtered and the solvent removed under reduced pressure to yield 40 gm of dark syrup. This was taken up in 200 mL methylene chloride and adsorbed onto 60 gm silica gel by evaporation of the solvent and fractionated on a 600 mL column of silica gel by flash chromatography using ethyl acetate:hexane (1:4) as  
25 eluent. Fractions containing the product were pooled and concentrated to a pale yellow oil weighing 33.08 gm. The R<sub>f</sub> value (silica gel; ethyl acetate:hexane 1:4) was 0.31, which is consistent with the product being glutarylacetone methyl ester as assessed by elemental analysis and the NMR spectrum of the product.

Adipoylacetone Methyl Ester

Adipoylacetone methyl ester (methyl 6, 8-dioxononanoate) was generated by reacting the magnesium complex of t-butyl acetoacetate with methyl adipoyl chloride. t-Butyl acetoacetate magnesium complex was synthesized as described above, and to

5 a suspension of the complex (10.6 gm; 50 mmole) in 25 mL of ether was added methyl adipoyl chloride (9.83 gm; 55 mmole). The addition was made dropwise with stirring under a reflux condenser. After the addition was complete, the mixture was refluxed for thirty minutes and allowed to cool. To the mixture was added 25 mL of 1.8M sulfuric acid and the two-phase mixture transferred to a 125 mL separatory

10 funnel. The aqueous layer was extracted with ether (3X25 mL) and the combined ether extracts were washed with brine (4X10 mL). The ether was evaporated and to the residue was added 100 mg of p-toluenesulfonic acid monohydrate. The mixture was heated to 170 degrees and evolution of gas monitored with a bubbler. When gas evolution had subsided, the dark mixture was allowed to cool and 50 mL of ether

15 was added. The solution was transferred to a one liter separatory funnel and extracted with ice-cold 2M sodium hydroxide (20, 10, 5 and 5 mL). The extracts were run directly into ice-cold 1.8M sulfuric acid (25 mL). The acidic suspension was extracted with methylene chloride (3X30 mL). The organic extracts were pooled and washed with 5% sodium bicarbonate (2X10 mL) and brine (2X10 mL), dried

20 over sodium sulfate, filtered and the solvent removed under reduced pressure to yield 7.05 gm of dark syrup. This was taken up in 50 mL methylene chloride and adsorbed onto 15 gm silica gel and fractionated on a column of silica gel by flash chromatography using ethyl acetate:hexane (1:4) as eluant. Fractions containing the product as determined by TLC were pooled and concentrated to a pale yellow oil

25 weighing 5.39 gm. The R<sub>f</sub> value (silica gel; ethyl acetate:hexane 1:4) was 0.30. Elemental analysis and NMR spectrum of the product was consistent with the expected material.

Glutarylacetone

Glutarylacetone, (5,7-dioxo octanoic acid), was generated from glutarylacetone methyl ester by hydrolysis. Briefly, glutarylacetone methyl ester (1.0 g) was hydrolyzed in 10 ml of 4.0 M HCl at 90° for 30 minutes. The solution was cooled 5 and extracted with four 25 ml portions of methylene chloride. After drying over magnesium sulfate and evaporation of the solvent, the residue was recrystallized from ether-hexane to give 0.3 g of crystalline 5, 7-dioxo octanoic acid.

Additional Synthesis

In addition to the above compounds, it will be appreciated that other 10 succinylacetone analogs or derivatives may be made according to the following proposed synthetic schemes.

Succinyl Trifluoroacetone Methyl Ester (Methyl 7,7,7-trifluoro 4,6-dioxoheptanoic acid) Methanol (250 mL) is added to magnesium shavings (15.91 gm; 654.5 mmole) containing 0.5 mL of carbon tetrachloride. The mixture refluxes as the metal 15 dissolved, and a cold water bath is used to control the reaction. After the mixture has completely dissolved and cooled, t-butyl 3-oxo-4,4,4-trifluorobutanoate (140.9 gm; 664.2 mmole) is added dropwise over ten minutes. This mixture was refluxed for one hour, cooled, filtered and the resulting solid collected and washed with cold methanol and dried under vacuum.

20 The magnesium complex of t-butyl 3-oxo-4,4,4-trifluorobutanoate (266.5 gm; 635 mmole) is suspended in 250 ml of anhydrous ether in a three-neck one liter round bottom flask and carbomethoxypropionyl chloride (100 gm; 664 mmole) added dropwise over fifteen minutes while the mixture is stirred from overhead. The dropping funnel is removed and the mixture refluxed for thirty minutes. The mixture 25 is cooled and 250 ml of 2N aqueous sulfuric acid slowly added. The mixture is transferred to a one liter separatory funnel and the layers separated. The aqueous layer is extracted with ether (2 X 150 ml) and the combined ether extracts washed with water (4 X 100 ml). The ether is evaporated and to the residual red oil is added 800 mg of toluene sulfonic acid monohydrate. The mixture is heated in an oil bath (with reflux condenser) to 175 degrees until evolution of gas ceases. The mixture is cooled and taken up in 500 ml of ether. The ether extracted with ice-cold 30

2M aqueous sodium hydroxide (175, 90, 50, and 35 ml), and the extracts run from the separatory funnel directly into 250 ml of ice-cold 1.8M aqueous sulfuric acid. The acidic suspension is extracted with methylene chloride (3 X 150 ml) and the combined organic extracts were washed with 5% aqueous sodium bicarbonate (2 X 5 100 ml) and brine (100 ml). The residue after evaporation of the methylene chloride may be purified by silica gel flash column chromatography using as eluant chloroform:methanol 97:3.

Succinyl Trifluoroacetone From The Methyl Ester

The methyl ester (2.53 gms; 11.61 mmole) is suspended in 18 mL water and 2 mL of conc. HCl added. The mixture is heated with stirring at 50 degrees for two hours or until all the material dissolved. The solvent is removed under reduced pressure (aspirator at 50 degrees) and the residue taken up in 18 mL water and 2 mL of conc. HCl added. Again, the solution is heated at 50 degrees for two hours at which time TLC (methylene chloride:methanol 97:3) should show no ester remained.

15 (UV and ferric chloride spray reagent; 2.7% w/v in 2N HCl). The solvent is once again removed under reduced pressure (water pump, 50 degrees) and 20 mL water added. The water is removed under reduced pressure (water pump, 50 degrees) and residual water removed by azeotroping with 50 mL of toluene. To the residue is added 50 mL ether and the solvent removed on the roto-vap. Finally, the residue is 20 taken up in 10 mL of hot ether and filtered. Addition of four mL of hexane to the filtrate initiates crystallization and the flask is chilled. Crystals may be removed by filtration and dried.

Methyl 2'2,4-Dioxobutyl) Esterate

The magnesium complex of  $\alpha$ -butyl acetooacetate (135 gm; 635 mmole) is 25 suspended in 250 ml of anhydrous ether in a three-neck one liter round bottom flask and mono-methyl phthaloyl chloride (192 gm; 664 mmole) is added over fifteen minutes while the mixture is stirred from overhead. The dropping funnel is removed and the mixture refluxed for thirty minutes. The mixture is cooled and 250 ml of 2N aqueous sulfuric acid slowly added. The mixture is transferred to a one liter 30 separatory funnel and the layers separated. The aqueous layer is extracted with ether (2 X 150 ml) and the combined ether extracts washed with water (4 X 100 ml). The

ether is evaporated and to the residual red oil is added 800 mg of toluene sulfonic acid monohydrate. The mixture is heated in an oil bath (with reflux condenser) to 175 degrees until evolution of gas has ceased. The mixture is cooled and taken up in 500 ml of ether. The ether is extracted with ice-cold 2M aqueous sodium hydroxide (175, 90, 50, and 35 ml), and the extracts run from the separatory funnel directly into 250 ml of ice-cold 1.8M aqueous sulfuric acid. The acidic suspension is extracted with methylene chloride (3 X 150 ml) and the combined organic extracts washed with 5% aqueous sodium bicarbonate (2 X 100 ml) and brine (100 ml). The residue after evaporation of the methylene chloride may be purified by silica gel flash column chromatography to yield the product.

#### 2(2,4-Dioxobutyl) Benzoate From the Acetyl Ester

The methyl ester (2.55 gms; 11.61 mmole) is suspended in 18 mL water and 2 mL of conc. HCl added. The mixture is heated with stirring at 50 degrees for two hours (all material had dissolved). The solvent is removed under reduced pressure (aspirator at 50 degrees) and the residue taken up in 18 mL water and 2 mL of conc. HCl added. Again, the solution is heated at 50 degrees for two hours at which time TLC (methylene chloride:methanol 97:3) will show no ester remaining. (UV and ferric chloride spray reagent; 2.7% w/v in 2N HCl). The solvent is once again removed under reduced pressure (water pump, 50 degrees) and 20 mL water added. The water is removed under reduced pressure (water pump, 50 degrees) and residual water removed by azeotroping with 50 mL of toluene. To the residue is added 50 mL ether and the solvent removed on the roto-vap. Finally, the residue is taken up in 10 mL of hot ether and filtered. Addition of four mL of hexane to the filtrate initiates crystallization and the filtrate is chilled. Crystals may be removed by filtration and dried.

3,5-Dioxohexylcyanide

The magnesium complex of t-butyl acetacetate (135 gm; 635 mmole) is suspended in 250 ml of anhydrous ether in a three-neck one liter round bottom flask and beta-cyano propionyl chloride (78.0 gm; 614 mmole) added dropwise over fifteen minutes while the mixture is stirred from overhead. The dropping funnel is removed and the mixture refluxed for thirty minutes. The mixture is cooled and 250 ml of 2N aqueous sulfuric acid is slowly added. The mixture is transferred to a one liter separatory funnel and the layers separated. The aqueous layer is extracted with ether (2 X 150 ml) and the combined ether extracts washed with water (4 X 100 ml).

10 The ether is evaporated and to the residual red oil is added 800 mg of toluene sulfonic acid monohydrate. The mixture is heated in an oil bath (with reflux condenser) to 175 degrees until evolution of gas has ceased. The mixture is cooled and taken up in 500 ml of ether. The ether is extracted with ice-cold 2M aqueous sodium hydroxide (175, 90, 50, and 35 ml). The extracts were run from the

15 separatory funnel directly into 250 ml of ice-cold 1.8M aqueous sulfuric acid. The acidic suspension is extracted with methylene chloride (2 X 150 ml) and the combined organic extracts washed with 5% aqueous sodium bicarbonate (2 X 100 ml) and brine (100 ml). The residue after evaporation of the methylene chloride may be purified by silica gel flash column chromatography using ethyl acetate: hexane 1:4 as

20 eluant.

5-(3,5-Dioxohexyl) Terephthalide

A mixture of the 3,5-dioxohexylcyanide (1.72 gm; 20 mmole), lithium azide (1.08 gm; 22 mmole) and sulfuric acid (one drop) in 10 ml dry dimethylformamide is heated to 100-120 degrees. Progress of the reaction may be checked by TLC (silica gel; chloroform:methanol 97:3). When no starting material remains, the reaction is cooled and 20 ml of water added. The reaction is taken to dryness under reduced pressure and the residue fractionated by silica gel flash column chromatography using methylene chloride: glacial acetic acid: methanol 100:3:3 as eluant. Fractions

30 containing the product may be pooled and concentrated.

Beta-Keto t-Butyldimethylsilyl Enol Ester of C<sub>13</sub>A Methyl Ester

To a solution of succinyl nona methyl ester (3.44 gm; 20 mmole) in 50 ml THF is added a 50% dispersion of sodium hydride in mineral oil (960 mg; 20 mmole) and the mixture stirred until gas evolution ceases. To the mixture of enolates 5 is added a solution of t-butyl dimethylsilyl chloride (3.32 gm; 22 mmole) in 50 ml THF dropwise with stirring. Sodium chloride is removed by filtration and the residue fractionated by silica gel flash chromatography using ethyl acetate: hexane as eluant.

Beta-Keto Isopropyl Enol Esters of SA Methyl Ester

To each of the purified t-butyldimethylsilyl enol ethers of SA methyl ester 10 (2.87 gm; 10 mmole) in THF cooled to -78 degrees is added tetrabutylammonium fluoride in THF (11 mmole). After thirty minutes at -78, 2-iodopropane (1.87 gm; 11 mmole) is added to the mixture and the reaction allowed to slowly reach room temperature. The solvent is removed under reduced pressure and the residue purified by silica gel flash chromatography to yield the isopropyl enol ethers.

15 Beta-Hydroxy Keto Derivatives of SA Methyl Ester

To a solution of each of the t-butyldimethylsilyl enol ethers of SA methyl ester (2.87 gm; 10 mmole) in 50 ml of isopropanol at -20 degrees is added sodium borohydride (420 mg; 11 mmole). When no starting material remains 20 tetrabutylammonium fluoride (2.33 gm; 11 mmole) is added and reaction progress followed by TLC. Work-up by silica gel column chromatography should yield the hydroxy keto derivatives.

It will be appreciated by those skilled in the art that an alternative approach to these compounds would be via catalytic hydrogenation of the enol double bond in the t-butyldimethylsilyl enol ether of SA methyl ester followed by fluoride mediated silyl 25 ether cleavage to yield the desired hydroxy keto derivatives.

Methyl 4,6,8-Trioxo Nonanoate

To the dilithium salt of 2,4,6-triiodine (0.4 gm; 20 mmole) in 50 ml dry THF is added carbomethoxypropyl chloroformate (2.01 gm; 22 mmole) dropwise with stirring at zero degrees. When the 2,4,6-triiodine is completely removed, the solvent 30 is removed under reduced pressure and the residue fractionated by flash

**chromatography on silica gel using methanol/hexane as eluant.**

It will be apparent to those skilled in the art that the above-described methyl esters could be converted to the corresponding carboxylic acids by appropriate methods.


Having described what applicants believe to be their invention, it is important to  
5 note that it will be apparent to those skilled in the art that there are many possible substitutions for the specific materials and methods shown above. It will be understood that these substitutions are intended to come within the scope of the following claim.

27.

**WHAT IS CLAIMED IS:**

**1. A method of treating disease comprising suppressing the effectiveness of a patient's immune system comprising administering to a patient a therapeutically effective amount of an analogue or derivative of succinylacetone.**

**5 2. The method as described in claim 1, wherein said analogue or derivative of succinylacetone comprises the formula:**



**10 wherein**

$$\text{n} = 1-6$$

$$\text{R} = \text{CH}_3, \text{CF}_3, -\text{C}_6\text{H}_4\text{Cl}, -\text{CH}_2, \text{or} -\text{CCH}_3$$

**15**

$$\text{R}', \text{R}'' = \text{H}, \text{F}, \text{CH}_3, \text{or} \text{CH}_2\text{CH}_2\text{COR}^{\text{IV}}$$

$$\text{R}''' = \text{H}, -\text{CO}_2\text{R}, -\text{P}(\text{OR}^{\text{IV}})_2, \text{CNHR}^{\text{IV}}, \text{or tetrazolyl}$$

$$\text{R}^{\text{IV}} = \text{H}, \text{or alkyl}$$

**20**

**3. The method as described in claim 2, wherein n = 2-6.**

**4. The method as described in claim 1, wherein said analogue or derivatives of succinylacetone are selected from the group consisting of succinylacetyl-proline-PEG, succinylacetone malonate ester, methyl-4-acetyl-5-oxohexanoate, succinylacetyl-NH-PEG, glutarylacetone, and adipoylacetone.**


41

5. The method of claim 4, wherein an effective amount of said analogue or derivatives of succinylacetone is about 10 milligrams-800 mg/kg body weight.
6. The method of claim 5, wherein said succinylacetone analogue or derivatives are administered with pharmaceutically acceptable excipients.
7. The method of claim 6, wherein said disease is an autoimmune disease.
8. The method of claim 7, wherein said disease is the rejection of organ or tissue transplants.
9. The method of claim 6, wherein said disease is graft versus host disease.
10. Immunosuppressive compositions useful for treating diseases comprising an analogue or derivative of succinylacetone.

42

11. Immunosuppressive compounds as described in claim 10, wherein said analogue or derivative of succinylacetone comprise the formula:

5



wherein

$$n = 1-6$$

10

$$R = \text{CH}_3, \text{CF}_3, -\text{CO}^{\text{IV}}, -\text{CH}_2, \text{or } -\text{CCH}_3$$

15

$$R^1, R^2 = \text{H}, \text{F}, \text{CH}_3, \text{or } \text{CH}_2\text{CH}_2\text{COR}^{\text{IV}}$$


$$R^3 = \text{H}, -\text{CO}_2\text{R}^{\text{IV}}, -\text{PO}(\text{OR}^{\text{IV}})_2, \text{CNHR}^{\text{IV}}, \text{or tetrazolyl}$$

$$R^4 = \text{H}, \text{or alkyl}$$

12. Immunosuppressive compounds as described in claim 11, wherein n = 2-6.

13. Immunosuppressive compositions as described in claim 10, wherein said derivatives of succinylacetone have the form:

20



wherein X is primary or secondary amino group.

14. Immunosuppressive compositions as described in claim 11, wherein said analogue or derivatives of succinylacetone are selected from the group consisting of succinylacetyl-proline-NH-PEG, succinyl-acetyl-NH-PEG, succinylacetone methyl ester, methyl-4-acetyl-5-oxohexanoate, glutaracetone and adipoylacetone.


43

15. Immunosuppressive compositions as described in claim 14 further including a physiologically acceptable excipient.

FIG. 1


NOT TAKEN INTO CONSIDERATION  
FOR THE PURPOSES  
OF INTERNATIONAL PROCESSING

2/4



3/4


FIG. 3



SUBSTITUTE SHEET

4/4

FIG. 4



SUBSTITUTE SHEET

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: too light can't read**

**IMAGES ARE BEST AVAILABLE COPY.**  
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.